Thelansis

  Postmenopausal osteoporosis is a condition that causes a progressive loss of bone tissue after natural or surgical menopause, leading to fractures within 15 to 20 years from the cessation of ovarian function. It is the most common form of primary osteoporosis. The drastic changes in estrogen and cytokine levels within the body are the main contributors to bone loss in postmenopausal osteoporosis. Postmenopausal osteoporosis therapies are broadly classified into two categories: antiresorptive and osteogenic (bone anabolic). Antiresorptives slow down bone resorption and suppress bone turnover, while bone anabolics increase bone formation without affecting resorption, thus leaving bone turnover unaltered. Fractures severely affect the quality of life of an individual and are becoming a significant public health problem due to the aging population. Osteoporosis is diagnosed using bone density measurements of the lumbar spine and proximal femur. Hormone replacement therapy (HRT) is ...